# **Equity Research**

April 22, 2022 BSE Sensex: 57912

ICICI Securities Limited is the author and distributor of this report

Q4FY22 result review and earnings revision

# **Technology**

Target price: Rs3,908

### **Earnings revision**

(%)	FY23E	FY24E
Sales	↓ 4.4	↓ 7.0
EBIT	↓ 4.4	↓ 7.0
EPS	↓ 3.2	↓ 5.9


Target price revision Rs3,908 from Rs4,413

### **Shareholding pattern**

	Sep '21	Dec '21	Mar '22
Promoters	74.2	73.9	73.9
Institutional			
investors	15.6	14.7	12.3
MFs and others	5.5	4.8	4.5
Fls/Bank	0.2	0.2	0.2
Insurance Cos.	0.0	0.0	0.0
FIIs	9.9	9.7	7.6
Others	10.2	11.4	13.8

Source: www.nseindia.com

### **Price chart**



### **Research Analysts:**

Aniket Pande
aniket.pande@icicisecurities.com
+91 22 6807 7573

Heenal Gada heenal.gada@icicisecurities.com +91 22 6807 7504

## **INDIA**



# **L&T Technology Services**

REDUCE Maintain

Unfavourable risk-reward, expensive valuations Rs4,244

LTTS reported a miss on revenue growth by 130bps at 3.1% QoQ USD (Isec:4.4%). In CC terms, revenues grew 3.6% QoQ. In terms of verticals, Transportation reported strong growth of 7.8% QoQ, followed by Plant Engineering (+3% QoQ). Telecom & Hi-tech grew 1.1% QoQ, while Industrial Products / Medical Devices remained largely flat sequentially. Management guided for organic growth of 13.5-15.5% YoY USD for FY23 which is way below our/consensus revenue growth estimate of ~19%. We believe the guidance is a bit conservative against the backdrop of the robust vertical and deal pipeline commentary. We forecast 14.5%/14% revenue growth for LTTS for FY23/24.

EBIT margin for the quarter stood at 18.6% (vs Isec: 18%), flat QoQ. We expect margins to remain range-bound in the near term (>18%) given supply side pressures and reinvestment back in the business for growth, and forecast margins of 18% for FY23/24. Headwinds from the return of travel and discretionary costs and wage inflation can be offset by a better margin profile in low-margin verticals, productivity gains and cost efficiencies.

In Q4, LTTS won a \$100 million plus deal in the EACV space – being chosen as the strategic engineering partner for a new-age electric VTOL (Vertical Takeoff and Landing) aircraft program. Deal bookings continue to be strong with a total of six deals worth more than \$10 million won in Q4, including a \$100 million plus deal in EACV and another \$25 million plus deal.

Our EPS estimates are reduced by 3.2%/6% for FY23/24 on account lower revenue growth guidance for FY23. Margin estimates remain intact at 18% for FY23/24. LTTS currently trades at 35x FY24E P/E for FY22-FY24E EPS CAGR of 16%, PEG of 2.1x.

While LTTS is well positioned to play the ERD theme and grow at premium rates, we do not find the risk-reward favourable. We value the stock at 32x (earlier 34x) FY24E EPS. Maintain REDUCE rating with a revised target price of Rs3,908 (prior: Rs4,413).

Market Cap	Rs448bn/US\$5.9bn
Reuters/Bloomberg	LTTS IN
Shares Outstanding (m	n) 105.5
52-week Range (Rs)	5916/2506
Free Float (%)	26.1
FII (%)	7.6
Daily Volume (US\$'000	) 23,039
Absolute Return 3m (%	) (11.6)
Absolute Return 12m (9	64.2
Sensex Return 3m (%)	(1.8)
Sensex Return 12m (%	) 22.6

Year to March	FY21	FY22	FY23E	FY24E
Revenue (Rs mn)	54,497	65,697	76,622	88,842
Net Income (Rs mn)	6,633	9,570	11,159	12,849
EPS (Rs)	63.3	91.0	106.1	122.1
% Chg YoY	(19.2)	43.6	16.6	15.2
P/E (x)	67.0	46.7	40.0	34.7
CEPS (Rs)	84.2	111.3	128.1	147.7
EV/E (x)	42.4	30.3	26.6	22.6
Dividend Yield	0.5	0.8	0.8	0.8
RoCE (%)	16.2	20.3	20.1	20.1
RoE (%)	21.3	25.1	24.6	23.9

▶ Revenue below estimates. Revenue for the quarter came in at US\$232mn, growth of +3.1% QoQ USD (Isec: 4.4% QoQ). In CC terms, revenues grew 3.6% QoQ. In terms of verticals, Transportation reported strong growth of 7.8% QoQ, followed by Plant Engineering (+3% QoQ). Telecom & Hi-tech grew 1.1% QoQ, while Industrial Products / Medical Devices remained largely flat sequentially.

North America and Europe reported tepid growth of 2.8%/0.8% QoQ respectively. India was robust at 9.5% QoQ, while RoW declined 1.6% QoQ.

Vertical commentary. Management is bullish on Transportation seeing good pipeline in connectivity and autonomous especially in the software side. Plant engineering is seeing broad-based growth across FMCG, O&G and Chemicals and steady growth is expected ahead. Industrial products growth was impacted on account of client-specific issues. However, this is temporary and with healthy pipeline, strong growth is expected ahead.

LTTS has set up a new business unit for Metaverse which should help in growth and profitability within Telecom segment. Further, the company is launching 5G lab and global development centers to capture demand across key segments. Medical is seeing a gradual increase in pipeline as clients spend on software and digital platforms.

- ▶ Outlook. Management guided for organic growth of 13.5-15.5% YoY USD for FY23. This was below our expectations of 19-20% YoY. We believe guidance is conservative against the backdrop of robust vertical and deal pipeline commentary. Management aspires to maintain EBIT margins at 18%+.
- ▶ Beat on margins. EBIT margin for the quarter stood at 18.6% (vs Isec: 18%). Margins were flat QoQ, +200bps YoY. During the quarter, offshore mix declined to 54.6% (vs 58.7% in Q3FY22). This was due to initial ramp-up of new deals in the quarter and management guided for offshore mix to move towards 57%.

Utilisation dropped 80bps QoQ to 75.1% on account of full impact of strong hiring in Q3FY22. This should gradually move to 78% levels. Attrition for the quarter increased 290bps QoQ to 20.4% and is likely to stay elevated in the near term.

Going forward, management expects headwinds from revenue mix change and utilisations which should be offset by economies of scale, currency depreciation and operational efficiencies. Regular wage cycle would be followed from Jul'22 after positive corrections made for critical talent in Jan'22.

▶ Net additions for the quarter were at 743. Fresher hiring has ramped up and for FY22, LTTS had hired ~3k freshers.

Table 1: Q4FY22 actuals vs estimates (INR mn)

	Q4FY22	Q3FY22	QoQ	Q4FY21	YoY	Q4FY22E I-Sec	vs our estimates
Sales (\$ m)	232	225	3.1%	198	17.5%	235	-1.3%
Rs mn							
Sales	17,561	16,875	4.1%	14,405	21.9%	17,702	-0.8%
EBIT Margin	18.6%	18.6%	1 bps	16.6%	205 bps	18.0%	64 bps
PBT	3,588	3,403	5.4%	2,612	37.4%	3,445	4.1%
Tax	956	907	5.4%	659	45.1%	918	4.1%
Tax Rate	26.6%	26.7%	-1 bps	25.2%	141 bps	26.7%	-1 bps
Reported PAT	2,620	2,488	5.3%	1,945	34.7%	2,519	4.0%
EPS	24.8	23.7	4.9%	18.5	33.9%	24.0	3.6%

Source: Company data, I-Sec research

**Table 2: Change in estimates** 

	Revised		Old		Change (%)	
	FY23E	FY24E	FY23E	FY24E	FY23E	FY24E
Rs mn						
Revenues	76,622	88,842	80,138	95,554	(4.4)	(7.0)
EBIT	13,722	15,992	14,354	17,200	(4.4)	(7.0)
EBIT margin	17.9	18.0	17.9	18.0	0bps	) Obps
EPS (Rs/share)	106.1	122.1	109.5	129.8	(3.2)	(5.9)
Revenues (US\$ mn)	1,008	1,154	1,054	1,241	(4.4)	(7.0)
Revenue growth (US\$, %)	14.5	14.4	19.4	17.7	-480bps	-320bps


Source: Company data, I-Sec research

**Table 3: Segmental growth (Q4FY22)** 

	Revenues			
	(US\$ mn)	QoQ (%)	YoY (%)	% of total
Total Revenues	232	3.1	17.5	100.0
Revenue by geography				
North America	145	2.8	19.1	62.3
Europe	37	0.8	13.6	16.1
India	34	9.5	30.7	14.5
RoW	16	(1.6)	(5.7)	7.0
Revenue by verticals		, ,	, ,	
Transportation	77	7.8	25.5	33.3
Industrial products	44	(0.5)	17.2	18.8
Telecom & Hi-tech	49	`1.1	11.4	21.0
Process Industry	36	3.0	16.5	15.4
Medical Devices	27	(0.2)	10.1	11.5
Client metrics				
Top 5 clients	40	2.5	25.5	17.2
Top 10 clients	66	2.3	23.6	28.3
Top 20 clients	101	2.4	16.7	43.5


Source: Company data, I-Sec research

Chart 1: LTTS reported 3.6% QoQ CC growth




Source: Company, I-Sec research

**Chart 2: Robust growth in Transportation** 




Source: Company, I-Sec research

**Chart 3: Industrial Products slightly declined** 




Source: Company, I-Sec research

**Chart 5: Steady growth in process industry** 




Source: Company, I-Sec research

**Chart 7: Stable margins sequentially** 




Source: Company, I-Sec research

Chart 4: Telecom& Hi-tech posted tepid growth




Source: Company, I-Sec research

Chart 6: Medical devices was largely flat




Source: Company, I-Sec research

Chart 8: Utilisations declined 80bps QoQ




Source: Company, I-Sec research

**Chart 9: Attrition increased in line with indutry** 




Source: Company, I-Sec research

**Chart 11: Continued hiring momentum** 




Source: Company, I-Sec research

**Chart 10: Offshore dropped sharply** 



Source: Company, I-Sec research

**Chart 12: Healthy client additions** 




Source: Company, I-Sec research

**Table 4: LTTS summary** 

Rs mn	FY18	FY19	FY20	FY21	FY22	FY23E	FY24E
USD Rev (mn)	580	723	787	737	880	1,008	1,154
YoY	20%	25%	9%	-6%	19%	15%	14%
Revenues	37,471	50,783	56,192	54,497	65,697	76,622	88,842
YoY	15.4%	35.5%	10.7%	-3.0%	20.6%	16.6%	15.9%
EBIT	4,923	8,116	9,277	7,891	12,005	13,722	15,992
Margin	13.1%	16.0%	16.5%	14.5%	18.3%	17.9%	18.0%
PAT	5,115	7,667	8,187	6,633	9,570	11,159	12,849
EPS (Rs)	50	74	78	63	91	106	122
Payout	38%	34%	32%	35%	39%	33%	29%
OCF	4,136	8,062	6,381	13,325	10,062	8,292	9,474
FCF	3,270	7,161	4,854	12,554	8,438	5,971	6,784
RoE	30%	35%	31%	21%	25%	25%	24%
P/E	85.0	57.6	54.2	67.0	46.7	40.0	34.7
	1 / 1 0	. 31.0	J-1.Z	31.0	10.7	10.0	0-1.1

Source: Company data, I-Sec research

# Chart 13: 1-year forward P/E



Source: Bloomberg, I-Sec research.

# Financial summary

**Table 5: Profit and loss statement** 

(Rs mn, year ending March 31)

	FY21	FY22	FY23E	FY24E
Revenue (US\$mn)	737	880	1,008	1,154
Total Income (Sales)	54,497	65,697	76,622	88,842
Operating Expenses	44,423	51,548	60,582	70,164
EBITDA	10,074	14,149	16,039	18,678
% margin	18.5	21.5	20.9	21.0
Depreciation & Amortisation	2,183	2,144	2,317	2,686
EBIT	7,891	12,005	13,722	15,992
% margin	14.5	18.3	17.9	18.0
Other Income	1,537	1,524	1,676	1,676
Interest expense	455	437	420	420
Recurring PBT	8,973	13,092	14,978	17,248
Tax expense	2,308	3,486	3,819	4,398
Recurr. profit before				
minority	6,665	9,606	11,159	12,849
Minority interest	(32)	(36)	-	-
Extraordinary items	-	-	-	-
Net Profit as restated	6,633	9,570	11,159	12,849

Source: Company data, I-Sec research

**Table 6: Balance sheet** 

(Rs mn, year ending March 31)

	FY21	FY22	FY23E	FY24E
Liabilities				
Share capital	210	211	211	211
Reserves and Surpluses	34,521	41,414	48,880	58,036
Net Worth	34,731	41,625	49,091	58,247
Minority Interest	101	137	137	137
Non-current Liabilities	4,915	5,359	5,359	5,359
Total Liabilities	39,747	47,121	54,587	63,743
Borrowings	-	-	-	-
Assets				
Fixed Assets	12,943	12,926	12,930	12,934
Other Non-current assets	2,760	3,871	3,871	3,871
Current assets	35,026	44,113	51,575	60,727
less: current liabilities	10,982	13,789	13,789	13,789
Net current assets	24,044	30,324	37,786	46,938
Total Assets	39,747	47,121	54,587	63,743
0 1 10	-			

Source: Company data, I-Sec Research

**Table 7: Cashflow statement** 

(Rs mn, year ending March 31)

	FY21	FY22	FY23E	FY24E
Op. CF before W Cap				
changes	9,619	13,712	16,039	18,678
Working Capital change	6,229	(87)	(3,927)	(4,806)
Taxes	(2,523)	(3,563)	(3,819)	(4,398)
Capex	(771)	(1,624)	(2,321)	(2,690)
Free Cashflow	12,554	8,438	5,971	6,784
CF from other Invst Act (Ex				
Capex)	(9,283)	(2,859)	1,676	1,676
Dividend paid	1	1	(0)	(0)
Others	(287)	-	-	-
Increase/(Decrease) in				
Cash	(2,198)	(3,633)	(3,693)	(3,693)

Source: Company data, I-Sec research

## **Table 8: Key ratios**

(Year ending March 31)

Trous straining transfer only	FY21	FY22	FY23E	FY24E
Per Share Data (Rs)				
Reported EPS	63.3	91.0	106.1	122.1
Book Value per share (BV)	84.2	111.3	128.1	147.7
Cash EPS	331.6	395.6	466.6	553.6
Dividend per share	22.0	35.0	35.0	35.0
Growth Ratios (%)				
Total Income (Sales) - US\$	(6.4)	19.5	14.5	14.4
Total Income (Sales)	(3.0)	20.6	16.6	15.9
EBITDA	(9.3)	40.5	13.4	16.5
Net Income	(19.0)	44.3	16.6	15.2
Reported EPS	(19.2)	43.6	16.6	15.2
	(12.2)	32.3	15.0	15.3
Valuation Ratios (x) P/E				
P/BV	67.0	46.7	40.0	34.7
EV / EBITDA	50.4	38.1	33.1	28.7
EV / Sales	12.8	10.7	9.1	7.7
	42.4	30.3	26.6	22.6
Operating Ratios	7.8	6.5	5.6	4.7
Other Income / PBT (%)	34.1	50.9	71.3	62.1
Effective Tax Rate (%)				
Fixed Asset Turnover (x)				
Receivables (days)	12.1	8.3	8.4	7.3
	25.7	26.6	25.5	25.5
Return/Profitability Ratios (%)	43.9	45.9	46.7	47.3
Net Income Margins	83	94	93	92
EBITDA Margins	-	-	-	-
RoCE (Based on Avg)				
RoNW (Based on Avg)				
Dividend Yield	12.2	14.6	14.6	14.5

Source: Company data, I-Sec research

This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet babbar@icicisecuritiesinc.com, Rishi agrawal@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors.

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

### **ANALYST CERTIFICATION**

I/We, Aniket Pande, MBA' Heenal Gada, CA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number - INH000000990. ICÍCI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the

report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as an entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICÍ Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category registration in teelising requirement within such pursuing a securities assessed to fine the securities of may be signed to such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical

information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.